Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of a Booster Dose of Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Hib Vaccine in 365-569 Days Old Healthy Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infants 365-569 days of age.~Exclusion Criteria:~* Subjects who already received a booster dose of Hib vaccine.~* History of serious reaction(s) following vaccination.~* Any vaccination within 7 days of study vaccination.~* Known or suspected immune impairment.

- Gender: ALL
- Minimum Age: 365 Days
- Maximum Age: 569 Days
- Healthy Volunteers: t

Study Arms:
- Arm 1 (Type: ACTIVE_COMPARATOR): None
- Arm 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).